Ocular GVHD (Graft-Versus-Host Disease) is an immune-mediated condition that develops after a bone marrow or stem cell transplant. Donor immune cells attack the tear glands and eye surface, causing dry eyes, burning, redness, and light sensitivity. Early specialist evaluation and treatment protect the eye surface and preserve vision long-term.
Ocular GVHD affects your eyes after a bone marrow or stem cell transplant. Donor immune cells target your tear glands and corneal surface. The condition can appear weeks, months, or even years after transplant. Early identification changes outcomes significantly.
This condition sits at the intersection of haematology and ophthalmology. Your transplant team and your eye doctor need to work together. Regular eye review is part of post-transplant care, not an optional extra.
What Is Ocular GVHD?
Graft-Versus-Host Disease (GVHD) is an immune-mediated inflammatory reaction. It occurs when donor immune cells recognise the recipient’s tissues as foreign and attack them. Several organs can be affected, including the skin, liver, gut, and eyes.
The eye is more commonly affected in chronic GVHD, but acute GVHD can also involve the ocular surface. When the eyes are involved, the condition is called Ocular GVHD.
What Are the Symptoms of Ocular GVHD?
Symptoms range from mild to severe. They include one or more of the following:
- Dry eyes and a persistent gritty sensation
- Burning and irritation
- Redness
- Excessive watering and tearing
- Light sensitivity
- Blurred or fluctuating vision
In children, obvious complaints are often absent. Parents may notice excessive eye rubbing, light sensitivity, or reluctance to open the eyes in bright light.
Do not dismiss vague symptoms such as discomfort, scratchiness, or eye fatigue. These can be early signs of ocular GVHD. Your transplant surgeon may request an eye evaluation even when you have no symptoms at all.
How Is Ocular GVHD Diagnosed?
A complete eye examination is the starting point. This includes visual acuity testing, refraction, slit-lamp examination, and tear film assessment.
Your eye doctor will also perform specific tests to evaluate the ocular surface. These include the Schirmer’s test, and staining of the cornea with fluorescein and/or Rose Bengal dyes. These tests assess tear production and identify surface damage not visible to the naked eye.
How Is Ocular GVHD Treated?
Management focuses on controlling dryness, reducing inflammation, preventing infection, and protecting the cornea from scarring.
Systemic drugs given by your bone marrow transplant team for the rest of the body often do not adequately treat the eyes. Your eye doctor will likely recommend one or more of the following:
- Lubricating eye drops to improve comfort and reduce corneal damage
- Steroid eye drops to control inflammation and prevent scarring
- Antibiotic eye drops to prevent or treat secondary infection
- Autologous serum eye drops to support healing of the ocular surface
- Cyclosporine eye drops to reduce the immune-mediated reaction
Treatment is adjusted over time based on disease activity and symptom burden. This is a condition that needs long-term follow-up, not a single course of treatment.
How is Ocular GVHD Classified?
Acute ocular GVHD develops during or soon after systemic acute GVHD and is characterized by sudden inflammation, redness, pain, tearing, photophobia, and conjunctival involvement.
Chronic ocular GVHD is a long-term immune-mediated disease that typically presents with persistent dry eye, burning, grittiness, fluctuating vision, meibomian gland dysfunction, and progressive ocular surface damage.
Acute-on-chronic ocular GVHD occurs when a patient with established chronic ocular GVHD experiences a sudden inflammatory flare, causing a rapid worsening of symptoms such as redness, pain, light sensitivity, and ocular surface inflammation on top of their baseline chronic dry eye disease.
Who Is Most at Risk?
Anyone who has undergone a bone marrow or stem cell transplant can develop ocular GVHD. Risk is higher in:
- Patients with chronic GVHD affecting other organs
- Patients on prolonged immunosuppression
- Those with a history of acute GVHD
Children who have had transplants are a particularly vulnerable group. Symptoms may be subtle. Eye problems can quietly affect reading, school performance, and daily comfort without an obvious complaint from the child.
When to See a Specialist
See an eye specialist promptly if any of the following apply.
You or your child has had a bone marrow or stem cell transplant, and eye symptoms have appeared at any point after — not only in the early weeks.
Symptoms are present but mild. Mild ocular GVHD does not stay mild without treatment. Surface damage accumulates quietly.
Your transplant team has not yet arranged an ophthalmic review. Ask for one. It should be part of standard post-transplant follow-up.
Vision feels “off” even though a recent check showed normal acuity. Tear film instability affects functional vision. Standard acuity testing does not capture it.
You have been given lubricants but the symptoms persist. This is a signal for specialist evaluation, not a reason to try a different brand of drops.
What Doctors Sometimes Miss
Ocular GVHD is underdiagnosed. Several patterns come up repeatedly in practice.
Symptoms labelled as “just dry eyes.” Post-transplant dryness is not routine dry eye. The mechanism is different, the severity is higher, and the risk of corneal scarring is real. It needs specialist evaluation, not over-the-counter drops.
Children who don’t complain. A child who rubs their eyes, squints, or avoids reading is not always being difficult. These are ocular surface symptoms. Parents and transplant teams both need to watch for them.
The quiet chronic phase. Acute GVHD gets attention. Chronic ocular GVHD can smoulder for months with low-grade symptoms. Vision may remain measurably normal while the surface continues to deteriorate. Symptom absence does not mean the eye is safe.
Delayed referral from transplant teams. Eye review is sometimes requested only after symptoms become severe. Baseline ophthalmic evaluation before or shortly after transplant is better practice. Earlier review means earlier intervention.
Ocular GVHD: Symptoms, Causes, and When to Worry
| Symptom | What It Means | When to Worry |
|---|---|---|
| Dryness and grittiness | Tear gland damage from donor immune cells | If persistent or worsening despite lubricants |
| Burning and irritation | Ocular surface inflammation | If affecting daily activities, reading, or sleep |
| Redness | Conjunctival involvement | If sudden, severe, or accompanied by pain |
| Light sensitivity | Corneal surface damage | If debilitating or new after a settled period |
| Blurred or fluctuating vision | Tear film instability or corneal changes | Always warrants prompt specialist review |
| Eye rubbing in children | May be the only visible sign | If post-transplant, refer early — do not wait |
| Watering and tearing | Reflex response to surface dryness | If combined with other symptoms |
FAQs
Can ocular GVHD occur without dry eye symptoms?
Yes. Some patients present with redness, light sensitivity, or blurred vision rather than classic dryness. In children, the only sign may be eye rubbing or reluctance to be in bright light. A specialist examination is more reliable than symptom-based self-assessment.
Does ocular GVHD go away on its own?
Occasionally it settles with time, but many patients need long-term treatment. Stopping treatment early often leads to flare-ups. Your eye doctor will guide when and how to taper any medications.
Can both eyes be affected?
Yes. Ocular GVHD typically affects both eyes, though one side may be more symptomatic than the other.
Is teleconsultation available for ocular GVHD follow-up?
Yes. If you live outside Gurgaon or are unable to travel, teleconsultation is available to support ongoing management in partnership with your local eye doctor.
This page is part of the Dry Eye Disease hub. Read about our full approach to GVHD, dry eyes, and children’s eye care. Please also read the Pediatric Eye Care hub.
Here’s another heartening patient story: A young boy and his love for trucks, and Chronic GVHD and Success Stories.
About the Author
This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.
She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.
As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.
1500+ Five Star Patient Reviews Google Business Profile
If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation
Read her research on PubMed | Google Scholar | ResearchGate | ORCID
Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735
Leave a review on Google
Read a patient story:
